Lab for Home 1

Boehringer Ingelheim acquires Pharmaxis' phase 1a drug

Boehringer

Boehringer Ingelheim and Pharmaxis announce that Boehringer Ingelheim has exercised its option and acquired the investigational drug PXS4728A, to develop it for the treatment of the liver-related condition NASH and to prevent its consequences.

Find out more

istock 000019115467 smaller1

Bronchitol Paediatric Cystic Fibrosis Clinical Trial Reports Positive Results

Pharmaceutical research company Pharmaxis (ASX: PXS) is pleased to announce positive results of its recently completed Phase II trial of Bronchitol® (mannitol) in children and adolescents with cystic fibrosis (CF). The trial, conducted across 39 global centres, met its primary endpoint and confirms that Bronchitol is efficacious in young patients, regardless of concomitant dornase alfa use.

Find out more

GP at Bennelong

Pharmaxis in the news

Bennelong Innovation Forum

Pharmaxis CEO Gary Phillips was a key speaker at the inaugural Bennelong Innovation Forum attended by the Minister for Health, Sussan Ley, at Macquarie University on 9 December.

 The Australian

Pharmaxis CEO Gary Phillips speaks to The Australian about policy to support the commercialisation of biomedical research.

Find out more